Researchers find protein that fuels repair of treatment-resistant cancer cells

Imagine you're fighting for your life but no matter how hard you hit, your opponent won't go down.

The same can be said of highly treatment-resistant cancers, such as head and , where during radiation and chemotherapy some cancer cells repair themselves, survive and thrive. Head and neck cancer is the sixth most common cancer in the world, but the late detection and treatment resistance result in a high mortality rate.

Now, University of Michigan researchers have found that a particular protein—TRIP13—encourages those cancer cells to repair themselves. And they have identified an existing chemical that blocks this mechanism for cell repair.

"This is a very significant advance, because identifying the function of the protein that fuels the repair of cancer cells and having an existing chemical that blocks the process, could speed the process of moving to clinical trials," said principal investigator Nisha D'Silva, U-M professor of dentistry and associate professor of pathology.

Typically, if scientists discover a promising drug therapy target, it takes years to develop drug compounds from scratch and move these into clinical trials.

If cell DNA is damaged and the cell cannot repair the damage, the cell dies. In head and neck cancers, D'Silva and colleagues showed that that overexpress TRIP13 were able to repair their DNA enough to survive and continue to grow as cancer.

"Targeting this repair mechanism with specific drugs could increase effectiveness of treatment and improve survival of patients," D'Silva said. "And given the overexpression of TRIP13 in several treatment-resistant cancers, this strategy will likely be important for multiple cancers."

More information: Nature Communications 31 Jul 2014. DOI: 10.1038/ncomms5527

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

The fine line between breast cancer and normal tissues

15 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

16 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

19 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

User comments